Creative Medical Technology Holdings got FDA clearance for its Phase 1/2 clinical trial for its StemSpine procedure using AlloStem, according to a Sept. 19 news release.
The study will enroll 30 patients with chronic lower back pain. They will recieve AlloStem, a non-surgical injection aimed to improve blood supply around the disc and lower back.
"With an opioid crisis in the United States, we believe that CELZ-201-DDT is potentially a more effective, sustainable, and safer non-surgical pain management option compared to opioids, and we look forward to advancing these studies," Timothy Warbington, CEO of Creative Medical Technology, said in the release.